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This article provides supplementary data for the paper “LC–MS/
MS method for simultaneous quantification of heparan sulfate
and dermatan sulfate in urine by butanolysis derivatization”
(Forni et al., 2018). Several parameters were tested to optimize
sample preparation by butanolysis in order to carry out
simultaneous quantifications of HS and DS by tandem mass
spectrometry.
Here we describe step-by-step instructions to perform HS
and DS analysis in urine samples using external calibration
curves of standards of known concentration. Sample are
quantified by interpolation from the calibration curve and
reported in mg/mL. Then, HS and DS are normalized to creati-
nine concentration and reported as mg/g uCr.
& 2018 The Authors. Published by Elsevier Inc. This is an open
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Rubject area Clinical Chemistry
ore specific subject area Heparan and Dermatan sulfates quantification in urine samples.
ype of data Figures
ow data was acquired Chromatographic separation of derivatized urine samples using an
Agilent 1260 Infinity HPLC capillary system with Kinetex Biphenyl
column 2.6 mm, 100  2.1mm (Phenomenex, Torrance, CA) coupled to
a AB Sciex QTRAP 5500 for MS/MS analysis.ata format Filtered and analyzed.
xperimental factors Derivatization of urine samples by butanolysis followed by LC–MS/MS
analysis for simultaneous quantification of heparan and dermatan sulfates.
xperimental features Optimization of butanolysis reaction conditions for deriving HS and DS.
Standard operating procedure for sample preparation.
Stability study.ata source location Florence, Italy.
ata accessibility Data is with this article.
elated research article Forni G, Malvagia S, Funghini S, Scolamiero E, Mura M, Della Bona M,
Villanelli F, Damiano R, la Marca G. LC–MS/MS method for simulta-
neous quantification of heparan sulfate and dermatan sulfate in urine
by butanolysis derivatization. Clin. Chim. Acta 488 (2018) 98–103 [1].Value of the data
 The described method allows the simultaneous quantitation of dermatan sulfate (DS) and heparan sulfate
(HS) in urine by LC–MS/MS, so as to facilitate differential diagnoses in MPS and targeted patient follow up.
 The protocol for preparing samples involves the chemical cleavage of glycosaminoglycans (GAGs)
in a butanolysis reaction. The high yield product permits a reproducible quantitation of HS and DS
even if a small amount of sample is used.
 The method could become a useful and reliable test in clinical laboratories where mass spectro-
metry is commonly used in several areas of diagnostics.
 Given that the method can be applied to different type of matrices including dried blood spots, it
could be modified and adapted for second tier testing of positive samples in newborn screening
programmes for lysosomal storage disorders.1. Data
The reported dataset includes five figures.
Figs. 1–4 provide experimental data for the optimization of time-temperature and reagent volume
parameters for butanolysis reaction of HS and DS.
Fig. 5 provides short-term stability data relating to storage conditions.
The details on the operating procedure for the quantitative analysis of HS and DS in human urine
are given below.
Fig. 2. Time lapse of HS butanolysis reaction over a period of 6 h at 90 °C.
Fig. 1. The y-axis represents the HS peak area resulting from three different incubation conditions. Boxes represent inter-
quartile ranges, and the horizontal line across each box indicates the median values. The “x” markers represent mean values.
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2.1. Operating procedure for sample preparation1. Keep the urine sample at room temperature until completely thawed. Gently invert the tube to
ensure that the urine specimen is homogeneous.
2. Filter 1–2mL of urine with 0.22-mm syringe filters (Merck KGaA, Darmstadt, Germany) and
transfer to 1.5mL tube.
3. Analyze all urine samples for creatinine in order to measure an equal concentration of urine for
each patient:
if the initial creatinine of the sample (i-uCr) is 4100 mg/mL:
a) dilute the filtered urine in deionized water until a final creatinine concentration (f-uCr) of 100 m
g/mL is reached:
iuCr=f uCr¼ dilution f actor
ba
b
Fig. 3. Optimization of DS butanolysis reaction conditions. Signal monitoring was performed during butanolysis over a period
of 6 h at 65 °C, (panel A). A shorter time investigation was tested at two different temperatures, 50 °C (blue line) and 65 °C
(red line), (panel B).
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Transfer 5 mL of urine (100 mg/L uCr) into each tube to reach an absolute value of creatinine of
500mg.If i-uCr o100 mg/mL:
) Use a volume of urine with an absolute value of creatinine of 500 mg
The calculation used is : 500=creatinine concentration ðmg=LÞ ¼ urine volume ðmLÞ:
) Label two glass screw-cap tubes for each patient sample. Transfer the calculated volume of urine
into each labelled tube.4. Dry the samples under a stream of nitrogen at 45 °C.
5. Add 75 mL of 3 N HCl in N-Butanol to each vial working in a fume hood to chemically cleave the
glycosaminoglycans. Close the tubes tightly and incubate in a thermostatically controlled oven as
follows:
HS samples at 90 °C for 60min;
DS samples at 65 °C for 25min.
6. Cool the samples to room temperature for 10min and dry under a stream of nitrogen at 45 °C.
7. Prepare a water/acetonitrile solution (30:70, v/v) containing 0.1% of formic acid. The solution is
stable for 1 month at room temperature.
8. Add 200 mL of solution to each HS tube and 800 mL to each DS tube.
9. Vortex for 15 s.
11
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1
1
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Fig. 4. The HS high-QC sample was incubated at 90 °C for 1 h with 75, 100, 150, 200 and 250 mL of 3N HCl in n-Butanol (red dots).
The DS high-QC sample was incubated at 60 °C for 25min with the same volumes of 3N HCl in n-Butanol used for HS (blue dots).
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(final volume 1mL)
1. Vortex for 15 s.
Samples can be kept for two days at 4–8 °C.2.2. Calibration standard solutions2. Prepare two stock solutions for DS and HS at a concentration of 3 and 1 g/L in water, respectively.
3. Prepare a calibration standard stock solution HS7 at 50mg/L by diluting 1:20 the stock solution at
1 g/L in water. Prepare calibration standard stock solutions from HS6 to HS1 by a serial dilution 1:2
from HS7 calibration standard stock solutions in water.
4. Prepare a calibration standard stock solution DS7 at 200mg/L by diluting 1:15 the stock solution at
3 g/L in water. Prepare DS6 to DS1 calibration standard stock solutions by a serial dilution 1: 2 from
DS7 in water.
5. The calibration standard stocks solutions are as follows:H
H
H
H
H
H
HHS calibration standard
stock solutionsConcentrations
(mg/L)DS calibration standard
stock solutionsConcentrations
(mg/L)S1 0.78 DS1 3.12
S2 1.562 DS2 6.25
S3 3.125 DS3 12.5
S4 6.25 DS4 25
S5 12.5 DS5 50
S6 25 DS6 100
S7 50 DS7 200
1
1
1
1
2
Fig. 5. Effect of different temperature storage (20, 4, 37 °C and room temperature) on stability of DS and HS in urine.
G. Forni et al. / Data in Brief 21 (2018) 2398–2404 24032.3. Preparation of an external calibration curve6. Dilute the synthetic urine with water until a final uCr of 200 mg/L is reached.
7. Prepare the calibration standards for HS and DS from 0 to 7 by adding 200 μL of each calibration
standard stock solution to 200 μL of synthetic urine (uCr 200 mg/L).
8. Transfer 5 mL of each calibration standard to a labeled tube and proceed to point 4.
Normalize the results value for urinary creatinine and express it as mg/g of uCr.2.4. Preparation of quality control samples9. Prepare the High and Low QC stock solutions for HS at 40mg/L and 2mg/L by diluting 1:25 and
1:500 the stock solution at 1 g/L in water, respectively.
0. Prepare the High QC stock solution for DS at 180mg/L by adding 90 μL of the stock solution at 3 g/L
to 1410 μL of water. Prepare the Low QC stock solution for DS at 6mg/L by diluting 1:500 the stock
solution at 3 g/L in water.
2G. Forni et al. / Data in Brief 21 (2018) 2398–240424041. Prepare the Low and High QC samples combining the same volume of each QC stock solution with
synthetic urine (uCr 200 mg/L) obtaining the following levels:Analyte QC samples mg/LS Low 1.0H
High 20.0S Low 3.0D
High 90.02.5. Optimization of sample preparation
In order to determine the optimal reaction conditions for HS derivatization, a set of experimental
runs was conducted to assess the effects of temperature, time and derivatization reagent volume
on yield.
Taking into account the results published by Trim [2], we tested temperatures around 100 °C.
Three sets of spiked samples with fixed HS concentration were incubated at 100, 90 and 80 °C and
analyzed every 30min. Each experiment was performed in six replicates to estimate the variability of
results.
The boxplot in Fig. 1 shows the median, interquartile range, and outliers for each dataset. A further
dataset was collected to determine the effect of incubation time on the HS peak area counts over a
period of 6 h at 90 °C (Fig. 2).
To establish the optimum reaction parameters for DS butanolysis the same experimental proce-
dure used for HS analysis was conducted.
In order to check if different volumes of derivatization reagent corrupt sensitivity, a set of samples
for each analyte was incubated with increased amounts of 3 N HCl in n-Butanol (Fig. 4)
QC samples with low and high concentrations were maintained at four different temperatures for
1 month and analyzed at regular time intervals (Fig. 5).Acknowledgements
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